Editas Medicine Company Profile (NASDAQ:EDIT)

About Editas Medicine

Editas Medicine logoEditas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDIT
  • CUSIP:
Key Metrics:
  • Previous Close: $23.54
  • 50 Day Moving Average: $19.58
  • 200 Day Moving Average: $16.82
  • 52-Week Range: $35,634,000.00 - $12.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.47
  • P/E Growth: 0.00
  • Market Cap: $838.82M
  • Outstanding Shares: 35,634,000
Profitability:
  • Net Margins: -1,184.46%
  • Return on Equity: -59.22%
  • Return on Assets: -31.66%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 14.80%
  • Quick Ratio: 14.80%
Additional Links:
Companies Related to Editas Medicine:

Analyst Ratings

Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $33.75 (43.37% upside)

Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
DateFirmActionRatingPrice TargetDetails
2/19/2017J P Morgan Chase & CoReiterated RatingHoldView Rating Details
2/15/2017Jefferies Group LLCReiterated RatingBuy$35.00View Rating Details
5/16/2016Cowen and CompanyReiterated RatingBuyView Rating Details
2/29/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$28.00View Rating Details
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Editas Medicine (NASDAQ:EDIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2017        
11/7/2016Q3($0.64)($0.59)$1.00 million$1.00 millionViewListenView Earnings Details
5/16/2016Q116($0.30)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
Current Year EPS Consensus Estimate: $-2.49 EPS
Next Year EPS Consensus Estimate: $-2.78 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.44)($0.44)($0.44)
Q3 20161($0.68)($0.68)($0.68)
Q4 20161($0.67)($0.67)($0.67)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership Percentage: 60.89%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Alexandra GlucksmannCOOSell6,000$20.58$123,480.00View SEC Filing  
2/15/2017Andrew A F HackCFOSell3,000$19.20$57,600.00View SEC Filing  
1/11/2017Andrew A F HackCFOSell15,000$19.20$288,000.00View SEC Filing  
12/7/2016Polaris Venture Management Co.Major ShareholderSell75,000$15.82$1,186,500.00View SEC Filing  
12/6/2016Kevin BittermanDirectorSell130,000$15.79$2,052,700.00View SEC Filing  
11/23/2016Kevin BittermanDirectorSell21,480$15.71$337,450.80View SEC Filing  
11/22/2016Polaris Venture Management Co.Major ShareholderSell12,819$15.77$202,155.63View SEC Filing  
11/15/2016Kevin BittermanDirectorSell88,900$16.96$1,507,744.00View SEC Filing  
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Editas Medicine (NASDAQ:EDIT)
DateHeadline
News IconChart Inspection on Shares of Editas Medicine Inc (EDIT) - Piedmont Register (NASDAQ:EDIT)
piedmontregister.com - February 24 at 5:40 PM
News IconStock Update for Editas Medicine, Inc. (NASDAQ:EDIT) - Midway Monitor (NASDAQ:EDIT)
midwaymonitor.com - February 24 at 5:40 PM
News IconInsider Trading at Editas Medicine Inc.? (NASDAQ:EDIT)
nyhetsbanken.info - February 23 at 2:45 AM
News IconEditas Medicine Inc. (NASDAQ:EDIT) Insider Ownership stands at 0.3 (NASDAQ:EDIT)
mundoaguaysaneamiento.net - February 23 at 2:45 AM
News IconStock Market Strong Start to the Week (NASDAQ:EDIT)
marketoracle.co.uk - February 22 at 5:11 PM
News IconInvestor Radar: Taking a Closer Look at Editas Medicine, Inc. (NASDAQ:EDIT) - BVN (NASDAQ:EDIT)
bvnewsjournal.com - February 22 at 7:16 AM
News IconWhat Analysts are Predicting For ACADIA Pharmaceuticals (ACAD), Editas Medicine (EDIT)? - The USA Commerce (NASDAQ:EDIT)
www.theusacommerce.com - February 22 at 7:16 AM
News IconSpot Check on Stock With Abnormal Activity Editas Medicine, Inc. (NASDAQ:EDIT) (NASDAQ:EDIT)
naijaoversabi.com - February 19 at 10:59 AM
News IconThe Charts For Editas Medicine, Inc. (EDIT) Is Speaking Volumes Today - NY Stock News (NASDAQ:EDIT)
nystocknews.com - February 18 at 4:36 PM
News IconAnd praises right-winger Rush Limbaugh for understanding him (NASDAQ:EDIT)
ekosvoice.com - February 18 at 9:52 AM
News IconThe Editas Medicine, Inc. (EDIT) Coverage Initiated at the JMP Securities (NASDAQ:EDIT)
mundoaguaysaneamiento.net - February 18 at 9:52 AM
News IconA fine red line between cures, enhancements using gene editing tech (NASDAQ:EDIT)
www.bioworld.com - February 17 at 6:22 PM
News IconEditas Medicine, Inc. (NASDAQ:EDIT) Insider Transactions Are in the Air (NASDAQ:EDIT)
xboxonezone.com - February 17 at 6:22 PM
News IconThe Birth of CRISPR Inc (NASDAQ:EDIT)
science.sciencemag.org - February 16 at 8:53 PM
News IconThe Birth of CRISPR Inc (NASDAQ:EDIT)
science.sciencemag.org - February 16 at 8:53 PM
News IconThere's a fine red line between cures, enhancements using gene editing tech (NASDAQ:EDIT)
www.bioworld.com - February 16 at 8:53 PM
globenewswire.com logoEditas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference (NASDAQ:EDIT)
globenewswire.com - February 16 at 8:53 PM
News IconThere's a fine red line between cures, enhancements using gene editing tech (NASDAQ:EDIT)
www.bioworld.com - February 16 at 8:53 PM
News IconEditas Medicine Inc (NASDAQ:EDIT) Reports USPTO Decision Positive To Broad Institute In CRISPR Intervention (NASDAQ:EDIT)
wallstreetpr.com - February 16 at 8:53 PM
News IconEditas Medicine Inc (NASDAQ:EDIT) Reports USPTO Decision Positive To Broad Institute In CRISPR Intervention (NASDAQ:EDIT)
wallstreetpr.com - February 16 at 8:53 PM
News IconEditas Medicine Inc (NASDAQ:EDIT) Reports USPTO Decision Positive To Broad Institute In CRISPR Intervention (NASDAQ:EDIT)
wallstreetpr.com - February 16 at 8:53 PM
fool.com logoWhy Fortress Investment Group, Editas Medicine, and Hertz Global Holdings Jumped Today (NASDAQ:EDIT)
us.rd.yahoo.com - February 16 at 8:53 PM
fool.com logoWhy Fortress Investment Group, Editas Medicine, and Hertz Global Holdings Jumped Today (NASDAQ:EDIT)
us.rd.yahoo.com - February 16 at 8:53 PM
fool.com logoWhy Fortress Investment Group, Editas Medicine, and Hertz Global Holdings Jumped Today (NASDAQ:EDIT)
us.rd.yahoo.com - February 16 at 8:53 PM
sg.finance.yahoo.com logoGene editing patent ruling sways fortune of biotech hopefuls (NASDAQ:EDIT)
us.rd.yahoo.com - February 16 at 8:53 PM
sg.finance.yahoo.com logoGene editing patent ruling sways fortune of biotech hopefuls (NASDAQ:EDIT)
us.rd.yahoo.com - February 16 at 8:53 PM
News IconMarket View: Looking at Shares of Editas Medicine Inc. (EDIT) - SKV News (NASDAQ:EDIT)
skvnews.com - February 16 at 3:53 PM
marketwatch.com logoEditas Medicine's stock soars after favorable ruling in CRISPR patent dispute - MarketWatch (NASDAQ:EDIT)
www.marketwatch.com - February 16 at 3:52 PM
benzinga.com logoEditas Medicine Higher After Favorable Patent Ruling - Benzinga (NASDAQ:EDIT)
www.benzinga.com - February 16 at 3:52 PM
livemint.com logoUse gene tools for disease, not designer babies: researchers (NASDAQ:EDIT)
www.livemint.com - February 15 at 3:51 AM
News IconInvestors are Watching Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - Piedmont Register (NASDAQ:EDIT)
piedmontregister.com - February 14 at 10:50 PM
bloomberg.com logoUse Gene Tools for Disease, Not Designer Babies, Researchers Say - Bloomberg (NASDAQ:EDIT)
www.bloomberg.com - February 14 at 5:48 PM
bloomberg.com logoUse Gene Tools for Disease, Not Designer Babies, Panel Says (NASDAQ:EDIT)
www.bloomberg.com - February 14 at 5:48 PM
reuters.com logoBRIEF-Flagship Ventures Fund reports a 9.4 percent passive stake in Editas Medicine as of Dec 31, 2016 - Reuters (NASDAQ:EDIT)
www.reuters.com - February 13 at 5:38 PM
finance.yahoo.com logoEditas Medicine to Present at Upcoming February Investor Conferences (NASDAQ:EDIT)
finance.yahoo.com - February 10 at 5:23 PM
News IconLevels in Focus on Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - Sherwood Daily (NASDAQ:EDIT)
sherwooddaily.com - February 10 at 3:31 AM
einnews.com logoGlobal CAS9 Technology Market is expected to reach around USD 1.8 Billion By 2022 (NASDAQ:EDIT)
www.einnews.com - February 7 at 2:58 AM
marketwatch.com logo10-K: ALEXANDRIA REAL ESTATE EQUITIES INC (NASDAQ:EDIT)
www.marketwatch.com - January 31 at 10:34 PM
4-traders.com logoEditas Medicine : Edit) Given Average Rating of Buy by Analysts (NASDAQ:EDIT)
www.4-traders.com - January 31 at 5:32 PM
News IconMA Levels in Review for Editas Medicine Inc. (EDIT) - Market Point (NASDAQ:EDIT)
mtptnews.com - January 30 at 5:48 PM
News IconWhat are Brokerage Firms Saying About Editas Medicine Inc (NASDAQ:EDIT)? - Aiken Advocate (NASDAQ:EDIT)
aikenadvocate.com - January 29 at 9:59 PM
News IconEditas Medicine Inc EDIT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:EDIT)
www.bioportfolio.com - January 27 at 6:32 PM
marketexclusive.com logoEditas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Financial Statements and Exhibits (NASDAQ:EDIT)
marketexclusive.com - January 25 at 6:07 PM
News IconMarket Focus- Increased Volatility Recorded on Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - Wall Street Beacon (NASDAQ:EDIT)
wsbeacon.com - January 24 at 10:34 PM
News IconPriming The Pump: Stock Volatility Spotted in Editas Medicine, Inc. (NASDAQ:EDIT) - Wall Street Beacon (NASDAQ:EDIT)
wsbeacon.com - January 24 at 3:16 AM
4-traders.com logoEDITAS MEDICINE, INC. : Financial Statements and Exhibits (form 8-K) (NASDAQ:EDIT)
www.4-traders.com - January 23 at 5:14 PM
biz.yahoo.com logoEDITAS MEDICINE, INC. Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:EDIT)
biz.yahoo.com - January 23 at 5:14 PM
insidermonkey.com logo10 Most Interesting Companies In The World (NASDAQ:EDIT)
www.insidermonkey.com - January 21 at 4:11 AM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Editas Medicine, Inc. (NASDAQ:EDIT) - Wall Street Beacon (NASDAQ:EDIT)
wsbeacon.com - January 17 at 5:45 PM
News IconFocus Equity: Stock Strength Indicator Update on Editas Medicine ... - Wall Street Beacon (NASDAQ:EDIT)
wsbeacon.com - January 17 at 8:06 AM

Social

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?

5 brokers have issued 1-year target prices for Editas Medicine's stock. Their forecasts range from $28.00 to $40.00. On average, they anticipate Editas Medicine's share price to reach $33.75 in the next year.

When will Editas Medicine announce their earnings?

Editas Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.

What are analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:

  • Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)
  • According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (1/10/2017)

Who owns Editas Medicine stock?

Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.43%), Viking Global Investors LP (4.80%), Deerfield Management Co. (4.80%), EcoR1 Capital LLC (1.76%), Foresite Capital Management III LLC (0.77%) and State Street Corp (0.30%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, James E Flynn, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co.

Who sold Editas Medicine stock? Who is selling Editas Medicine stock?

Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including Clarius Group LLC. Company insiders that have sold Editas Medicine stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co.

Who bought Editas Medicine stock? Who is buying Editas Medicine stock?

Editas Medicine's stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Foresite Capital Management III LLC, Highland Capital Management LP, Clough Capital Partners L P, A.R.T. Advisors LLC, Russell Investments Group Ltd., FMR LLC and State Street Corp.

How do I buy Editas Medicine stock?

Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Editas Medicine stock cost?

One share of Editas Medicine stock can currently be purchased for approximately $23.54.

Editas Medicine (NASDAQ:EDIT) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Earnings History Chart

Earnings by Quarter for Editas Medicine (NASDAQ:EDIT)

Dividend History Chart

Dividend Payments by Quarter for Editas Medicine (NASDAQ:EDIT)

Last Updated on 2/27/2017 by MarketBeat.com Staff